Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

So Far So Good: With Phase III Data, Keryx Says Zerenex Will Stand Out In ESRD Crowd

This article was originally published in The Pink Sheet Daily

Executive Summary

Company set to price drug up to 20% below Genzyme's market leading Renvela/Renagel franchise, and ponders impact of new Medicare bundling regime for phosphate binders used in end-stage renal disease.
Advertisement

Related Content

Keryx Aims For Ironclad Hold On Hyperphosphatemia Market
Zerenex To Be Positioned As Cost-Saving, Oral Alternative In ESRD Setting
As Keryx Moves Closer To Phase III Results, Partnership Options Heat Up
As Keryx Moves Closer To Phase III Results, Partnership Options Heat Up
Chronic Kidney Disease Drug Developers Jockey For Position In Era Of Change
Chronic Kidney Disease Drug Developers Jockey For Position In Era Of Change
Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen
Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen

Topics

Advertisement
UsernamePublicRestriction

Register

PS071554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel